K.T. Flaherty

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

P. Ascierto, I. Krajsová, A. Arance, 2024, European journal of cancer.